7-OH Federal Status: DEA Scheduling Timeline (October 2026)

Status as of 21 October 2026: No federal temporary scheduling order for 7-OH has been published. On 14 October 2026 DEA published a new notice of intent to place 7-OH and mitragynine pseudoindoxyl (MP) in Schedule I above a defined threshold, and said the order "will be published in the Federal Register on or after November 13, 2026" (91 FR 65370). MP, MGM-15 and MGM-16 have been in Schedule I since 26 August 2026, and SR-17018 and three related compounds since 27 August 2026. State law is separate: the same DEA notice lists ten states that already prohibit 7-OH.

This page is the reference point on this site for federal action on 7-hydroxymitragynine (7-OH) and related compounds. It lists every federal step since July 2025 with its Federal Register citation, explains what the October 2026 threshold covers, and shows how to check the record yourself. It was last verified against the Federal Register on 21 October 2026. It does not ask readers to take any action.

Federal timeline, July 2025 to October 2026

Dates below are publication dates. Where a document has a Federal Register (FR) citation, it is given in full.

Date

Federal action

Source

15 July 2025

FDA announces seven warning letters (dated June 2025) to companies marketing 7-OH products such as tablets, gummies, drink mixes and shots.

FDA release

29 July 2025

FDA recommends a scheduling action to control certain 7-OH products under the Controlled Substances Act.

FDA release

2 December 2025

US Marshals seize about 73,000 units of 7-OH products, valued at about $1 million, from three Missouri firms.

FDA release

19 March 2026

H.R. 8000 (END 7-OH Act) introduced in the House.

govinfo

1 July 2026

DEA announces intent to temporarily schedule 7-OH and three related substances. A separate notice for SR-17018 and three related compounds publishes the same day.

DEA release; 91 FR 39940

6 July 2026

Notice of intent for 7-OH above a threshold (docket DEA-1570). Notice of intent for MP, MGM-15 and MGM-16. HHS opens a request for information on the threshold (docket HHS-OASH-2026-0232), comments due 31 July.

91 FR 40917; 91 FR 40909; 91 FR 41049

5 August 2026

Earliest date the July notice allowed a 7-OH order to publish. No order followed.

91 FR 40917

8 August 2026

S. 5383 (End Gas Station Heroin Act) introduced in the Senate.

govinfo

17 August 2026

FDA Import Alert 54-15 (kratom) updated; the new entry names a 7-OH product.

FDA Import Alert 54-15

26 August 2026

Temporary order places MP, MGM-15 and MGM-16 in Schedule I, effective that day until 26 August 2028. HHS extends its comment period to 10 September.

91 FR 54948; 91 FR 55104

27 August 2026

Temporary order places SR-17018 and three related compounds in Schedule I, effective that day until 27 August 2028.

91 FR 55252

10 September 2026

HHS comment period on the threshold closes.

91 FR 55104

7 October 2026

Senators Grassley, Lee and Collins write to DEA and FDA asking for the 7-OH order to be finalized and for permanent scheduling.

Senate letter

8 October 2026

HHS sends DEA a letter recommending a new threshold for 7-OH and MP (as described in the 14 October notice).

91 FR 65370

14 October 2026

New notice of intent for 7-OH and MP above a threshold (docket DEA-1570), with the July 7-OH notice withdrawn. Reissued notice of intent for MGM-15 and MGM-16 (docket DEA-1644), same approach as before.

91 FR 65370; 91 FR 65381

On or after 13 November 2026

Earliest date DEA says the new 7-OH and MP order can publish. Nothing had been published as of 21 October 2026.

Federal Register, DEA documents

What the 14 October threshold covers

The 14 October notice applies to 7-OH and MP, including their isomers, esters, ethers and salts. Either substance alone, or both combined, would be in Schedule I if a product meets either of two tests:

  • Concentration test: greater than 1 mg per gram for solid forms (powders, capsules, other solids), or greater than 1 mg per mL for liquids.
  • Ratio test: the mass of mitragynine divided by the mass of 7-OH (or MP, or both combined) is less than 100.

Meeting either test is enough. FDA's 7-OH page says HHS chose this approach to separate products "intentionally enhanced or concentrated" from products whose alkaloid makeup is "more consistent with botanical kratom" (FDA). It replaces the July 2026 proposal, which used 0.050 percent or more than 1.00 mg of 7-OH per article (91 FR 40917).

What the threshold does not cover, or change

The order would not schedule mitragynine itself, and it would not place below-threshold material in Schedule I. That is not a finding of safety. DEA writes that "neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels," and that it "still views kratom and its two major psychoactive ingredients, mitragynine and 7-hydroxymtragynine, as drugs of concern" (spelling as in the original, 91 FR 65370).

FDA rules apply whatever the threshold. FDA states that there are no FDA-approved 7-OH drugs, that 7-OH is not lawful in dietary supplements and that it cannot be lawfully added to conventional foods (FDA, 29 July 2025). The DEA notice also says the federal action "does not preempt more restrictive state law."

What changes on the day an order publishes

All points below come from the text of the 14 October notice (91 FR 65370), checked on 21 October 2026.

  • Effective on publication. The order "will take effect on the date the order is published in the Federal Register." There is no waiting period after that date.
  • Two years, plus a possible one. It remains in effect for two years, "with a possible extension of an additional year," while DEA runs the permanent scheduling process under 21 U.S.C. 811(a).
  • Full Schedule I controls. Covered material becomes subject to Schedule I regulatory controls and administrative, civil and criminal sanctions for manufacture, distribution, import, export, research and possession.
  • No court review of the temporary order. The notice states: "Temporary scheduling orders are not subject to judicial review," citing 21 U.S.C. 811(h)(6). A later permanent scheduling decision would be subject to judicial review.
  • No public comment step. DEA says the notice-and-comment rules of the Administrative Procedure Act do not apply to this notice of intent.
  • MP changes order. The August MP order (no threshold) stays in effect until the new order publishes and the old one is withdrawn, so there is no gap in control.

Compounds already in Schedule I

Compound

In Schedule I since

Order runs until

Citation

Mitragynine pseudoindoxyl (MP, also MGPI)

26 August 2026, any amount

26 August 2028, or until replaced by the new 7-OH and MP order

91 FR 54948

MGM-15 (dihydro-7-hydroxymitragynine)

26 August 2026, any amount

26 August 2028, or until replaced by the reissued order

91 FR 54948

MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine)

26 August 2026, any amount

26 August 2028, or until replaced by the reissued order

91 FR 54948

SR-17018 (5,6-dichloro desmethylchlorphine), 5,6-dichloro brorphine, N-propionitrile chlorphine, spirochlorphine

27 August 2026

27 August 2028

91 FR 55252

DEA describes MP as "a chemical rearrangement product of 7-hydroxymitragynine" and MGM-15 as a derivative of 7-OH (91 FR 54948). For background on each compound, see what 7-OH is and how it relates to MP and MGM-15 and our reference page on MGM-15.

Pending legislation

  • H.R. 8000, End Needless Distribution of 7-OH Act. Introduced 19 March 2026 by Rep. Gus Bilirakis and referred to the Energy and Commerce and Judiciary committees (govinfo; co-sponsor release). It would schedule synthetic 7-OH in Schedule I.
  • S. 5383, End Gas Station Heroin Act. Introduced 8 August 2026 by Sen. Bernie Moreno and referred to the Senate Judiciary Committee (govinfo). It would schedule MGM-15 and MGM-16, and synthetic 7-OH and MP above a threshold.

As of 21 October 2026, govinfo lists only the introduced version of each bill, and neither has passed a chamber. Separately, the 7 October 2026 letter from Senators Grassley, Lee and Collins asks DEA to permanently schedule 7-OH, MP, MGM-15 and MGM-16, and to consider scheduling the whole kratom plant.

Federal status and state status are different questions

Federal scheduling sets a national floor. The 14 October DEA notice lists ten states that prohibit 7-OH (Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Massachusetts, Tennessee, Vermont and Wisconsin) and says Arizona, Colorado, South Carolina and Texas cap it (91 FR 65370). In California, a 9 January 2026 letter from the state health department says selling kratom and 7-OH products for consumption is unlawful (CDPH). State rules are tracked on our 7-OH and kratom laws by state page and our Tennessee kratom and 7-OH ban page.

How to check the Federal Register yourself

Secondhand reports can run ahead of the official record. The Federal Register is the only place a temporary scheduling order becomes legally effective, and checking it takes a few minutes.

  1. Open the Drug Enforcement Administration page on federalregister.gov and look at the newest documents.
  2. Look for a title containing "Temporary Placement of 7-Hydroxymitragynine." Check the document type: a "Proposed Rule" is a notice of intent, while a "Rule" with a DATES line saying the order is effective is the order itself.
  3. Check public inspection, where documents are posted for viewing before their official publication date.
  4. Once an order is in effect, temporary listings appear in 21 CFR 1308.11(h) on eCFR.

The same documents are published on govinfo, the Government Publishing Office archive.

Frequently asked questions

When does the federal 7-OH ban start?

No start date has been set. DEA says the temporary order "will be published in the Federal Register on or after November 13, 2026" and will take effect on the day it publishes (91 FR 65370). "On or after" is a minimum, not a fixed date: the July notice gave 5 August 2026 and no order followed.

Is 7-OH Schedule I yet?

Not as of 21 October 2026. No temporary scheduling order for 7-OH appears in the Federal Register or on public inspection (DEA documents). MP, MGM-15 and MGM-16 have been Schedule I since 26 August 2026 (91 FR 54948).

How long does a temporary scheduling order last?

Two years from publication, with a possible extension of one more year if permanent scheduling proceedings are under way (91 FR 65370). DEA says it intends to pursue permanent scheduling of 7-OH and MP through formal rulemaking.

Is the 7-OH comment period still open?

No. The HHS request for information on the threshold (docket HHS-OASH-2026-0232) closed on 10 September 2026 (91 FR 55104). DEA states that the 14 October notice of intent is not subject to notice-and-comment requirements.

Does the federal action ban kratom?

The proposed order does not schedule mitragynine or the kratom plant. It covers 7-OH and MP only above the stated threshold (91 FR 65370). Some states restrict kratom more broadly, and three senators have asked DEA to consider scheduling the whole plant (Senate letter).

Sources